|
|
Toxicity
evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant
1716) in patients with recurrent malignant glioma
Rampling
R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R,
MacLean A, Harland J, McKie E, Mabbs R, Brown M
Beatson
Oncology Centre, Western Infirmary, Glasgow, UK
The
herpes simplex virus (HSV) ICP34.5 null mutant 1716 replicates selectively in
actively dividing cells and has been proposed as a potential treatment for
cancer, particularly brain tumours.
We present a clinical study to evaluate the safety of 1716 in patients with
relapsed malignant glioma.
Following intratumoural inoculation of doses up to 10(5) p.f.u., there was no
induction of encephalitis, no adverse clinical symptoms, and no reactivation of
latent HSV.
Of nine patients treated, four are currently alive and well 14-24 months after
1716 administration.
This study demonstrates the feasibility of using replication-competent HSV in
human therapy.
PMID:
10845724 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10845724&dopt=Abstract
|
